Wednesday, 26 August 2026European Markets

DNO Stock Bullish Momentum With A 14.41% Rise Today

Loading stream...

(VIANEWS) - The Market ended the session with DNO (DNO.OL) jumping 14.41% to kr11.75 on Monday, after four sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 1.26% to kr1,208.60, after five successive sessions in a row of gains, on what was an all-around up trend exchanging session today.

About DNO

DNO ASA engages in the exploration, development, and production of oil and gas assets in the Middle East, the North Sea, and West Africa. Its flagship project is the Tawke field that is located in the Kurdistan region of Iraq. The company was founded in 1971 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, DNO has a trailing twelve months EPS of kr-2.43.

Volatility

DNO's last week, last month's, and last quarter's current intraday variation average was a positive 0.56%, a negative 0.89%, and a positive 1.95%.

DNO's highest amplitude of average volatility was 1.41% (last week), 2.48% (last month), and 1.95% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DNO's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for DNO is 6287070 which is 64.52% above its average volume of 3821230.

More news about DNO (DNO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com